



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 33/26, 33/06, 33/24

(11) International Publication Number:

WO 99/15189

A1

(43) International Publication Date:

1 April 1999 (01.04.99)

(21) International Application Number:

PCT/GB98/02834

(22) International Filing Date:

18 September 1998 (18.09.98)

(30) Priority Data:

9720061.2

19 September 1997 (19.09.97) GB

(71) Applicant (for all designated States except US): CROSFIELD LIMITED [GB/GB]; Bank Quay, Warrington, Cheshire WAS IAB (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROBERTS, Norman, Bryson [GB/GB]; Royal Liverpool University Hospitals, Prescot Street, Liverpool L7 8XP (GB). WEBB, Maurice [GB/GB]; 117 Green Lane, Vicars Cross, Chester, Cheshire CH3 5LD (GB). RANKIN, Benjamin, Joseph [GB/GB]; University of Liverpool, Senate House, Abercromby Square, Liverpool L69 3BX (GB).

(74) Agents: COLEIRO, Raymond et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR. BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METAL COMPOUNDS, MIXED OR SULPHATED, AS PHOSPHATE BINDERS

(57) Abstract

A mixed metal compound for pharmaceuties the type of the total weight of phosphate present over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30 % by weight of the total phosphate present, over a pH range from 2-8.